首页> 外文期刊>Clinical advances in hematology & oncology: H&O >Advances in drug development: New approaches to thyroid cancer
【24h】

Advances in drug development: New approaches to thyroid cancer

机译:药物开发的进展:甲状腺癌的新方法

获取原文
获取原文并翻译 | 示例
           

摘要

EC Thyroid cancer is not uncommon. Approximately 200,000 individuals within the United States have been diagnosed with thyroid cancer. The incidence is approximately 20,000 diagnoses per year. The sizeable difference between incidence and prevalence reflects the fact that most patients survive. The prognosis is excellent for the most part. For instance, the 5-year survival rate for papillary thyroid cancer is over 90%, and the prognosis for fol-licular thyroid cancer is close to that. There are, however, subtypes that carry a worse prognosis, the most notorious being anaplastic thyroid cancer. Fortunately, this entity makes up only 1-2% of all thyroid cancers.
机译:EC甲状腺癌并不少见。在美国,大约有200,000个人被诊断出患有甲状腺癌。每年大约诊断20,000次。发病率和患病率之间的巨大差异反映了大多数患者都能幸存的事实。大多数情况下预后良好。例如,甲状腺乳头状癌的5年生存率超过90%,而甲状腺癌的预后也接近这一水平。但是,有些亚型的预后较差,最臭名昭著的是间变性甲状腺癌。幸运的是,该实体仅占所有甲状腺癌的1-2%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号